Product Code: RA100476
Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral, Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales Forecast
The oncology precision medicine market is valued at USD 130 billion in 2023 growing at a CAGR of 8.93% during the forecast period 2023-2035.
Cancer is globally acknowledged as one of the most lethal diseases, characterized by its widespread occurrence and high mortality rates. As per data from the World Health Organization, in 2020 alone, there were approximately 20 million new cases of cancer and 10 million cancer-related deaths reported annually, with projections indicating a staggering 60% increase in these figures by the year 2040. The rise in cancer prevalence and pathogenesis is attributed to various factors including alcohol consumption, obesity, viral infections, exposure to radiation and chemicals. Traditional treatment methods for cancer, such as surgery, radiation therapy, and chemotherapy, are commonly employed. Additionally, there are complementary or alternative therapeutic approaches like hormone therapy, immunotherapy, and nanotherapy. However, these treatments have shown limitations in addressing the intrinsic genetic abnormalities underlying cancer, which can stem from specific mutations in oncogenes, tumor suppressor genes, and DNA repair genes. To overcome the limitations of existing treatments, the concept of precision medicine, also known as personalized medicine, has emerged. Precision medicine utilizes genomic information to develop targeted therapies tailored to individual patients. By analyzing tumor characteristics, genetic data, patient lifestyle, and environmental factors, precision medicine offers promising potential in treating cancer by moving away from a one-size-fits-all approach.
Individuals with a family history of certain cancers are at higher risk of inheriting the condition, and precision oncology enables them to undergo genetic testing to assess their risk. Early cancer screening facilitates early detection, leading to improved treatment outcomes. Notably, several precision cancer centers like MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic Cancer Center in the US provide advanced technologies and treatments tailored for patients with rare or challenging cancers. Clinical trials of oncology precision medicines have demonstrated high efficacy, leading to increased participation of volunteers and consequently expanding the patient pool in such trials. This aids researchers in making better-informed decisions regarding evaluated drugs or technologies. With ongoing research and innovation in precision medicine, there is an anticipated significant increase in the adoption of targeted drugs, thereby driving growth in the oncology precision medicine market in the foreseeable future.
Key Market Segments
Type of Cancer Targeted
Bladder Cancer
Blood / Hematologic Cancer
Breast Cancer
Cervical Cancer
Gastrointestinal Cancer
Head and Neck Squamous Cell Cancer
Lung Cancer
Skin Cancer
Others
Route of Administration
Oral
Intravenous
Others
Type of Molecule
Small Molecules
Biologics
Drug Class
Kinase Inhibitors
Enzyme Inhibitors
Immune Checkpoint Inhibitors
Others
Leading Drug Developers
Merck
Pfizer
AstraZeneca
Johnson $ Johnson Innovative Medicine
Genentech
Key Geographical Regions
North America (US, Canada)
Europe (France, Germany, Italy, Spain and UK)
Asia (China, Japan, Korea and India)
Middle East and North Africa (UAE, Israel, Qatar and Rest of Middle East and North Africa)
Latin America (Brazil, Argentina, Chile and Rest of Latin America)
Research Coverage:
The report studies the oncology in precision market based on type of cancer targeted route of administration, type of molecule, drug class, key geographical regions.
The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
The report forecasts the revenue of market segments with respect to five major regions
An overview of precision medicine, particularly in the field of oncology, is provided along with a comparison to traditional cancer medications. The process of developing oncology precision medicines is outlined, and the advantages they offer are discussed, highlighting their anticipated significance in shaping the future of personalized healthcare. Additionally, challenges associated with oncology precision medicine are addressed in this chapter.
The report provides an overview of oncology in precision medicine, including its evolution, types, and application areas. It also covers the benefits of these procedures compared to traditional beauty treatments and the side effects associated with them. The chapter also covers the key drivers of growth, new technologies, key issues and future prospects in this field.
Comprehensive analysis of the current landscape of oncology in precision medicine developers considering parameters such as establishment year, company size, headquarters, stage of development, approval body, approval region, drug designation, type of molecule, drug class, route of administration, dosage regimen, patient population and type of cancer targeted. Additionally, the chapter presents a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on several relevant parameters, such as stage of development, type of molecule, drug class and type of cancer targeted.
In-depth profiles of companies offering precision medicine, focusing on company overviews, financial information (where available), portfolio, recent advancements, and informed future prospects.
An analysis of partnerships established in this sector since 2018, covering clinical trial agreement, commercialization agreement, drug development agreement, drug development and commercialization agreement, drug distribution agreement, drug licensing agreement, manufacturing agreement, merger / acquisition, process development and manufacturing agreement, research agreement, research and development agreement, service agreement, technology utilization agreement and others.
A thorough examination of completed or ongoing clinical trials in the field of oncology precision medicine is conducted, focusing on several key parameters including trial registration year, patient enrollment numbers, trial phase, status, target patient demographics, gender distribution, types of cancer targeted, sponsorship or collaboration types, study design characteristics, intervention models, and trial purposes. The analysis also identifies the most active sponsors or collaborators, comprising both industry and non-industry players based on their sponsorship of clinical trials. Additionally, emerging focus areas and geographical trends are explored within this clinical trial analysis.
A case study is presented on developers of precision oncology assay kits, offering a detailed analysis across several parameters including development stage (commercialized and under development), regulatory certification and compliance, regional availability, test type, sample type, biomarker detection principle, turnaround time, cancer type targeted, and end-user demographics. Furthermore, the chapter includes insights on various assay kit developers, along with an analysis based on parameters such as establishment year, company size, and headquarters location.
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the oncology precision medicine market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Key Market Companies
AbbVie
Anticancer Bioscience
Astellas Pharma
Astrazeneca
Bayer
Blueprint Medicines
Bristol Myers Squibb
Eli Lilly
Erasca
Genentech
GlaxoSmithKline
Hutchmed
IDEAYA Biosciences
Jiangsu Hengrui Pharmaceuticals
Johnson & Johnson Innovative Medicine
Merck
Novartis
Pfizer
Repare Therapeutics
Roche
Seagen
SpringWorks Therapeutics
Takeda Pharmaceutical
VERAXA Biotech GmbH
VRise Therapeutics
TABLE OF CONTENTS
1. PREFACE
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
- 3.2.2.1. Overview of Major Currencies Affecting the Market
- 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
- 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
- 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
- 5.1. Chapter Overview
- 5.2. Precision Medicine
- 5.2.1. Evolution of Precision Medicine
- 5.3. Oncology Precision Medicine
- 5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine
- 5.3.2. Steps Involved in Developing Oncology Precision Medicine
- 5.3.3. Advantages Associated with Oncology Precision Medicine
- 5.3.3.1. Benefits to the Patients
- 5.3.3.2. Benefits to the Healthcare Providers
- 5.3.3.3. Benefits to the Cancer Researchers
- 5.3.4. Challenges Associated with Oncology Precision Medicines
- 5.3.5. Future Perspectives
6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE
- 6.1. Chapter Overview
- 6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape
- 6.2.1. Analysis by Stage of Development
- 6.2.2. Analysis by Approval Body
- 6.2.3. Analysis by Approval Region
- 6.2.4. Analysis by Drug Designation
- 6.2.5. Analysis by Type of Molecule
- 6.2.6. Analysis by Drug Class
- 6.2.7. Analysis by Route of Administration
- 6.2.8. Analysis by Dosage Regimen
- 6.2.9. Analysis by Patient Population
- 6.2.10. Analysis by Type of Cancer Targeted
- 6.2.11. Analysis by Stage of Development and Type of Cancer Targeted
- 6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape
- 6.3.1. Analysis by Stage of Development
- 6.3.2. Analysis by Type of Molecule
- 6.3.3. Analysis by Drug Class
- 6.3.4. Analysis by Type of Cancer Targeted
- 6.4. Oncology Precision Medicine: Developer Landscape
- 6.4.1. Analysis by Year of Establishment
- 6.4.2. Analysis by Company Size
- 6.4.3. Analysis by Location of Headquarters (Region)
- 6.4.4. Analysis by Location of Headquarters (Country)
- 6.4.5. Analysis by Company Size and Location of Headquarters (Region)
- 6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines
7. DETAILED COMPANY PROFILES
- 7.1. Chapter Overview
- 7.2. AstraZeneca
- 7.2.1. Company Overview
- 7.2.2. Financial Information
- 7.2.3. Oncology Precision Medicine Portfolio
- 7.2.4. Recent Developments and Future Outlook
- 7.3. Genentech
- 7.3.1. Company Overview
- 7.3.2. Financial Information
- 7.3.3. Oncology Precision Medicine Portfolio
- 7.3.4. Recent Developments and Future Outlook
- 7.4. Jiangsu Hengrui Pharmaceuticals
- 7.4.1. Company Overview
- 7.4.2. Oncology Precision Medicine Portfolio
- 7.4.3. Recent Developments and Future Outlook
- 7.5. Johnson & Johnson Innovative Medicine
- 7.5.1. Company Overview
- 7.5.2. Financial Information
- 7.5.3. Oncology Precision Medicine Portfolio
- 7.5.4. Recent Developments and Future Outlook
- 7.6. Novartis
- 7.6.1. Company Overview
- 7.6.2. Financial Information
- 7.6.3. Oncology Precision Medicine Portfolio
- 7.6.4. Recent Developments and Future Outlook
- 7.7. Pfizer
- 7.7.1. Company Overview
- 7.7.2. Financial Information
- 7.7.3. Oncology Precision Medicine Portfolio
- 7.7.4. Recent Developments and Future Outlook
- 7.8. SpringWorks Therapeutics
- 7.8.1. Company Overview
- 7.8.2. Oncology Precision Medicine Portfolio
- 7.8.3. Recent Developments and Future Outlook
8. SHORT COMPANY PROFILES
- 8.1. Chapter Overview
- 8.2. AbbVie
- 8.3. Anticancer Bioscience
- 8.4. Astellas Pharma
- 8.5. Bayer
- 8.6. Blueprint Medicines
- 8.7. Bristol Myers Squibb
- 8.8. Eli Lilly
- 8.9. Erasca
- 8.10. GlaxoSmithKline
- 8.11. Hutchmed
- 8.12. IDEAYA Biosciences
- 8.13. Merck
- 8.14. Repare Therapeutics
- 8.15. Roche
- 8.16. Seagen
- 8.17. Takeda Pharmaceutical
- 8.18. VERAXA Biotech
- 8.19. VRise Therapeutics
9. PARTNERSHIPS AND COLLABORATIONS
- 9.1. Chapter Overview
- 9.2. Partnership Models
- 9.3. Oncology Precision Medicine: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Drug Involved
- 9.3.6. Analysis by Type of Cancer Targeted
- 9.3.7. Most Active Players: Analysis by Number of Partnerships
- 9.3.8. Analysis by Geography
- 9.3.8.1. Local and International Agreements
- 9.3.8.2. Intracontinental and Intercontinental Agreements
10. CLINICAL TRIAL ANALYSIS
- 10.1. Chapter Overview
- 10.2. Scope and Methodology
- 10.3. Oncology Precision Medicine: Clinical Trial Analysis
- 10.3.1. Analysis by Trial Registration Year
- 10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
- 10.3.3. Analysis by Trial Phase
- 10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
- 10.3.5. Analysis by Trial Registration Year and Trial Phase
- 10.3.6. Analysis by Trial Status
- 10.3.7. Analysis by Trial Registration Year and Trial Status
- 10.3.8. Analysis by Target Patient Population
- 10.3.9. Analysis by Patient Gender
- 10.3.10. Analysis by Type of Cancer Targeted
- 10.3.11. Analysis by Type of Sponsor / Collaborator
- 10.3.12. Analysis by Study Design
- 10.3.12.1. Analysis by Type of Trial Masking
- 10.3.12.2. Analysis by Type of Intervention Model
- 10.3.12.3. Analysis by Type of Intervention
- 10.3.12.4. Analysis by Trial Purpose
- 10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials
- 10.3.13.1. Analysis by Leading Industry Players
- 10.3.13.2. Analysis by Leading Non-Industry Players
- 10.3.14. Word Cloud Analysis: Emerging Focus Areas
- 10.3.15. Analysis by Geography
- 10.3.15.1. Analysis of Clinical Trials by Geography
- 10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
- 10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status
11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS
- 11.1. Chapter Overview
- 11.2. Oncology Precision Medicine: Assay Kits
- 11.2.1. Analysis by Stage of Development
- 11.2.2. Analysis by Regulatory Certification / Compliance
- 11.2.3. Analysis by Regional Availability
- 11.2.4. Analysis by Type of Test
- 11.2.5. Analysis by Type of Sample Used
- 11.2.6. Analysis by Principle of Biomarker Detection
- 11.2.7. Analysis by Turnaround Time
- 11.2.8. Analysis by Type of Cancer Targeted
- 11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted
- 11.2.10. Analysis by End-user
- 11.2.11. Analysis by Regional Availability and End-user
- 11.2.12. Analysis by Type of Cancer Targeted and End-user
- 11.3. Oncology Precision Medicine Assay Kits: Developer Landscape
- 11.3.1. Analysis by Year of Establishment
- 11.3.2. Analysis by Company Size
- 11.3.3. Analysis by Location of Headquarters (Region)
- 11.3.4. Analysis by Location of Headquarters (Country)
- 11.3.5. Analysis by Company Size and Location of Headquarters (Region)
- 11.3.6. Analysis by Business Model
- 11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits
12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE
- 12.1. Chapter Overview
- 12.2. Technologies Used in Precision Medicine
- 12.2.1. Next Generation Sequencing in Precision Medicine
- 12.2.2. Nanotechnology in Precision Medicine
- 12.2.3. Molecular Imaging Technologies in Precision Medicine
- 12.2.4. Omics Technologies in Precision Medicine
- 12.2.5. Artificial Intelligence (AI) in Precision Medicine
- 12.3. Conclusion
13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
- 13.1. Chapter Overview
- 13.2. Market Drivers
- 13.3. Market Restraints
- 13.4. Market Opportunities
- 13.5. Market Challenges
- 13.6. Conclusion
14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET
- 14.1. Chapter Overview
- 14.2. Assumptions and Methodology
- 14.3. Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 14.4. Scenario Analysis
- 14.4.1 Conservative Scenario
- 14.4.2. Optimistic Scenario
- 14.5. Key Market Segmentations
15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED
- 15.1. Chapter Overview
- 15.2. Key Assumptions and Methodology
- 15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
- 15.3.1. Bladder Cancer: Forecasted Estimates (2023-2035)
- 15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (2023-2035)
- 15.3.3. Breast Cancer: Forecasted Estimates (2023-2035)
- 15.3.4. Cervical Cancer: Forecasted Estimates (2023-2035)
- 15.3.5. Gastrointestinal Cancer: Forecasted Estimates (2023-2035)
- 15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (2023-2035)
- 15.3.7. Lung Cancer: Forecasted Estimates (2023-2035)
- 15.3.8. Skin Cancer: Forecasted Estimates (2023-2035)
- 15.3.9. Other Cancers: Forecasted Estimates (2023-2035)
- 15.4. Data Triangulation and Validation
16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION
- 16.1. Chapter Overview
- 16.2. Key Assumptions and Methodology
- 16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
- 16.3.1. Oral: Forecasted Estimates (2023-2035)
- 16.3.2. Intravenous: Forecasted Estimates (2023-2035)
- 16.3.3. Others: Forecasted Estimates (2023-2035)
- 16.4. Data Triangulation and Validation
17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE
- 17.1. Chapter Overview
- 17.2. Key Assumptions and Methodology
- 17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
- 17.3.1. Small Molecules: Forecasted Estimates (2023-2035)
- 17.3.2. Biologics: Forecasted Estimates (2023-2035)
- 17.4. Data Triangulation and Validation
18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS
- 18.1. Chapter Overview
- 18.2. Key Assumptions and Methodology
- 18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
- 18.3.1. Kinase Inhibitors: Forecasted Estimates (2023-2035)
- 18.3.2. Enzyme Inhibitors: Forecasted Estimates (2023-2035)
- 18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (2023-2035)
- 18.3.4. Others: Forecasted Estimates (2023-2035)
- 18.4. Data Triangulation and Validation
19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS
- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
- 19.3.1. North America: Forecasted Estimates (2023-2035)
- 19.3.1.1. US: Forecasted Estimates (2023-2035)
- 19.3.1.2. Canada: Forecasted Estimates (2023-2035)
- 19.3.2. Europe: Forecasted Estimates (2023-2035)
- 19.3.2.1. France: Forecasted Estimates (2023-2035)
- 19.3.2.2. Germany: Forecasted Estimates (2023-2035)
- 19.3.2.3. Italy: Forecasted Estimates (2023-2035)
- 19.3.2.4. Spain: Forecasted Estimates (2023-2035)
- 19.3.2.5. UK: Forecasted Estimates (2023-2035)
- 19.3.3. Asia: Forecasted Estimates (2023-2035)
- 19.3.3.1. China: Forecasted Estimates (2023-2035)
- 19.3.3.2. Japan: Forecasted Estimates (2023-2035)
- 19.3.3.3. Korea: Forecasted Estimates (2023-2035)
- 19.3.3.4. India: Forecasted Estimates (2023-2035)
- 19.3.4. Middle East and North Africa: Forecasted Estimates (2023-2035)
- 19.3.4.1. UAE: Forecasted Estimates (2023-2035)
- 19.3.4.2. Israel: Forecasted Estimates (2023-2035)
- 19.3.4.3. Qatar: Forecasted Estimates (2023-2035)
- 19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (2023-2035)
- 19.3.5. Latin America: Forecasted Estimates (2023-2035)
- 19.3.5.1. Brazil: Forecasted Estimates (2023-2035)
- 19.3.5.2. Argentina: Forecasted Estimates (2023-2035)
- 19.3.5.3. Chile: Forecasted Estimates (2023-2035)
- 19.3.5.4. Rest of Latin America: Forecasted Estimates (2023-2035)
- 19.4. Data Triangulation and Validation
20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS
- 20.1. Chapter Overview
- 20.2. Key Assumptions and Methodology
- 20.3. Blockbuster Commercialzied Oncology Precision Medicine Market: Sales Forecast
- 20.3.1. ADCETRIS® Sales Forecast
- 20.3.2. Alecensa® Sales Forecast
- 20.3.3. ALUNBRIG® Sales Forecast
- 20.3.4. Avastin® Sales Forecast
- 20.3.5. Ayvakit® Sales Forecast
- 20.3.6. Braftovi®+ Mektovi® Sales Forecast
- 20.3.7. BRUKINSA® Sales Forecast
- 20.3.8. CALQUENCE® Sales Forecast
- 20.3.9. DARZALEX® Sales Forecast
- 20.3.10. Elunate® Sales Forecast
- 20.3.11. Empliciti® Sales Forecast
- 20.3.12. Enhertu® Sales Forecast
- 20.3.13. IBRANCE® Sales Forecast
- 20.3.14. ICLUSIG® Sales Forecast
- 20.3.15. IMBRUVICA® Sales Forecast
- 20.3.16. IMFINZI® Sales Forecast
- 20.3.17. INLYTA® Sales Forecast
- 20.3.18. Keytruda® Sales Forecast
- 20.3.19. Kadcyla® Sales Forecast
- 20.3.20. LENVIMA® / KISPLYX® Sales Forecast
- 20.3.21. Lumakras® / Lumykras® Sales Forecast
- 20.3.22. Mekinist® Sales Forecast
- 20.3.23. NERLYNX® Sales Forecast
- 20.3.24. NINLARO® Sales Forecast
- 20.3.25. Opdivo® Sales Forecast
- 20.3.26. Padcev® Sales Forecast
- 20.3.27. Piqray® Sales Forecast
- 20.3.28. Sprycel® Sales Forecast
- 20.3.29. Tabrecta® Sales Forecast
- 20.3.30. Tagrisso® Sales Forecast
- 20.3.31. Tasigna® Sales Forecast
- 20.3.32. Tecentriq® Sales Forecast
- 20.3.33. VENCLEXTA® Sales Forecast
- 20.3.34. Verzenio® / Verzenios Sales Forecast
- 20.3.35. Xospata® Sales Forecast
- 20.3.36. Xtandi® Sales Forecast
- 20.3.37. ZEJULA® Sales Forecast
- 20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast
- 20.4.1. Apatinib / Rivoceranib Sales Forecast
- 20.4.2. Elunate® Sales Forecast
- 20.5. Phase III Oncology Precision Medicine Market: Sales Forecast
- 20.5.1. Darovasertib / IDE196 Sales Forecast
- 20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast
- 20.5.2. Elenestinib / BLU-263 Sales Forecast
- 20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast
- 20.5.3. Elunate® Sales Forecast
- 20.5.3.1. Elunate® Sales Forecast by Type of Cancer Targeted
- 20.5.3.2. Elunate® Regional Sales Forecast
- 20.5.4. ORPATHYS® Sales Forecast
- 20.5.4.1. ORPATHYS® Regional Sales Forecast
- 20.5.5. Pyrotinib Sales Forecast
- 20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted
- 20.5.5.2. Pyrotinib Regional Sales Forecast
- 20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast
- 20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast
- 20.5.7. ZOLINZA® Sales Forecast
- 20.5.7.1. ZOLINZA® Regional Sales Forecast
21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS
- 21.1. Chapter Overview
- 21.2. Key Assumptions and Methodology
- 21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers
- 21.4. Data Triangulation and Validattion
22. CONCLUSION
23. EXECUTIVE INSIGHTS
- 23.1. Chapter Overview
- 23.2. Allarity Therapeutics
- 23.2.1. Company Snapshot
- 23.2.2. Interview Transcrip
- 23.3. Elephas
- 23.3.1. Company Snapshot
- 23.3.2. Interview Transcript
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS